On March 14, 2025, GlaxoSmithKline Limited (GSK) in Kenya officially rebranded to Haleon Kenya Limited, marking a significant shift towards a dedicated focus on consumer health.
This transition aligns with GSK’s global strategy to separate its consumer healthcare division, allowing Haleon to emerge as an independent entity committed to delivering high-quality, science-led health solutions tailored for Kenyan consumers.
Haleon was launched as an independent consumer health company on July 18, 2022, following its demerger from GSK. The name ‘Haleon’ combines the words ‘Hale,’ an old English word meaning ‘in good health,’ and ‘Leon,’ associated with strength. This rebranding reflects the company’s mission to enhance everyday health with humanity.
Haleon Kenya Limited inherits a robust portfolio of trusted brands that have been integral to Kenyan households. These include:
- Sensodyne: A leading toothpaste brand designed for sensitive teeth, offering relief and long-lasting protection.
- Panadol: A widely used analgesic providing effective pain relief and fever reduction.
- Eno: An antacid brand that offers quick relief from acidity and indigestion.
- Scott’s Emulsion: A cod liver oil supplement rich in vitamins A and D, supporting overall health.
These brands are trusted by millions globally and are now under the Haleon umbrella, reinforcing the company’s commitment to consumer health.
Haleon Kenya Limited operates a state-of-the-art production facility on Likoni Road, Nairobi. This site plays a crucial role in the country’s oral healthcare and pain relief landscape, producing millions of units annually of leading brands such as Sensodyne, Aquafresh, and Panadol. Beyond meeting local demand, the facility serves as a regional hub, exporting to seven East African markets and South Africa.
In 2024, Haleon Kenya Limited achieved Net Carbon Zero (NCZ) certification, underscoring its dedication to sustainable operations. The company has invested in solar energy, powering its Likoni Road facility with solar panels to reduce reliance on non-renewable energy sources and significantly lower its carbon footprint. Additionally, Haleon received Alliance for Water Stewardship and True Waste certifications, reinforcing its commitment to environmental stewardship.
Haleon’s transition in Kenya is part of a broader global strategy to focus on consumer health. The company is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange. Annual sales amounted to around £10 billion across 120 markets in 2020, positioning Haleon as a global leader in consumer healthcare.
